Thermo Fisher Scientific IL-27 p28 Monoclonal Antibody (3D1p28), eFluor 660, eBioscience

Applications

Tested Dilution

Publications

Flow Cytometry (Flow)

5 µL (0.03 µg)/test

-

Product Specifications

Host/Isotype

Mouse / IgG1, kappa

Recommended Isotype Control

Mouse IgG1 kappa Isotype Control (P3.6.2.8.1), eFluor™ 660, eBioscience™

Class

Monoclonal

Type

Antibody

Clone

3D1p28

Immunogen

Recombinant IL-27

Conjugate

eFluor™ 660 eFluor™ 660 eFluor™ 660

Excitation/Emission Max

651/668 nm View spectra

Form

Liquid

Concentration

5 µL/Test

Storage conditions

4° C, store in dark, DO NOT FREEZE!

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_11150252

Product Specific Information

Description: This 3D1p28 monoclonal antibody reacts with the human p28 subunit of IL-27. Interleukin-27 (IL-27) is a member of the IL-12 family, a subgroup of the IL-6 family of cytokines. It is a heterodimer of the subunits EBI3 (Epstein-Barr Virus Induced Gene 3), which is homologous to the p40 subunit shared by IL-12 and IL-23, and p28 (IL-30), which is homologous to p35. IL-27 is produced by activated dendritic cells and macrophages in response to TLR ligands and inflammatory cytokines. IL-27 has been shown to have both pro-inflammatory and anti-inflammatory effects. It influences the commitment of CD4+ T-cells toward the Th1 lineage by inducing the expression of the transcription factor T-bet and the upregulation of IL-12R beta2. Its anti-inflammatory functions include the suppression of Th2 and Th17 proliferation and differentiation.

The IL-27 receptor shares one subunit, gp130, with other members of the IL-6 family. The subunit WSX-1 (IL-27R alpha, TCCR) is unique to IL-27 and is believed to be the only part of the receptor that interacts with the cytokine. IL-27R activation leads to the phosphorylation of Jak/STAT proteins, with STAT1 and STAT3 being critical to the function of IL-27.

Recent evidence suggests that the p28 subunit may also be secreted independently of EBI3 and have functions distinct from the IL-27 heterodimer: it is believed to not only antagonize the activity of IL-27, but also inhibit signaling of other gp130 ligands, such as IL-6 and IL-11.

Applications Reported: This 3D1p28 antibody has been reported for use in intracellular staining followed by flow cytometric analysis.

Applications Tested: This 3D1p28 antibody has been pre-titrated and tested by intracellular staining followed by flow cytometric analysis. This can be used at 5 µL (0.03 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

eFluor® 660 is a replacement for Alexa Fluor® 647. eFluor® 660 emits at 659 nm and is excited with the red laser (633 nm). Please make sure that your instrument is capable of detecting this fluorochome.

Excitation: 633-647 nm; Emission: 668 nm; Laser: Red Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

IL-27, a member of the IL-12 family, is a heterodimeric protein consisting of the p40-related protein Epstein-Barr virus-induced gene 3 (EBI3) non-covalently linked to an IL-12p35-related protein, p28 (also known as IL-30). IL-27 is produced by activated APCs and mature dendritic cells. IL-27 exerts its activities on NK cells and naive CD4+ T cells; mRNA expression analysis of IL-27 receptor components (WSX-1/TCCR and gp130) suggests that IL-27 may also target other cells, including mast cells and monocytes. Binding of IL-27 to WSX-1/gp130 activates JAK1, STAT1, and STAT3 and STAT1/3 phosphorylation. WSX-1/TCCR-deficient mice develop impaired Th1 responses and are more susceptible to infection with L. monocytogenes suggesting that Th1 responses require IL-27. Although activation of WSX-1 is required for the initiation of Th1 responses, it is not necessary for maintaining Th1 responses. IL-27 alone is not able to induce the differentiation of CD4+ T cells into IFN-γ-producing cells, suggesting a role for IL-27 as an initial activator of Th1 responses. An important effect of IL-27 in initiating Th1 responses is the induction of the Th1-specific transcription factor T-bet as well as the suppression of the Th2-specific transcription factor GATA-3. T-bet plays a critical role in Th1 differentiation by its ability to maintain IL-12Rβ2 expression following CD4+ T cell activation. Recent studies indicate that IL-27 has a potent antitumor activity. In vitro, IL-27 has been found to act directly on naive CD8 cells, generating CTL with enhanced granzyme B expression. In vivo, IL-27 has been reported to augment CTL activity, inhibit tumor growth, and induce complete regression of primary and metastatic neuroblastoma tumors.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.